Active Studies

This prospective, single-arm study evaluates the impact of GLP-1RA or GLP-1RA/GIP agonists on muscle and bone health in 20 patients with type 2 diabetes. Investigators utilize advanced PET/CT imaging at baseline, 3, 6, and 12 months to quantify changes in intramuscular fat, bone blood flow, and glucose metabolism following medication initiation. The study also tracks longitudinal changes in physical function through grip strength, gait speed, and Timed Up and Go assessments. The primary objective is to characterize early markers of sarcopenia and bone fragility to assist in the development of clinical prediction tools for patients at high risk of frailty. Findings aim to guide the integration of bone-protecting therapies or physical therapy for patients prescribed semaglutide or tirzepatide.

This prospective observational study evaluates the role of the gut microbiome in modulating response to semaglutide in participants with diabetes and obesity. The primary objective is to determine whether baseline and longitudinal differences in gut microbial composition are associated with variability in treatment effectiveness and gastrointestinal tolerability among individuals receiving GLP-1 receptor agonist therapy. Participants will be followed over 12 months with study assessments at baseline, 3, 6, and 12 months. Data collection includes stool samples, bloodwork, body measurements, and validated questionnaires assessing diet, physical activity, medication adherence, and gastrointestinal symptoms. Clinical data will be obtained from medical records where available to support evaluation of metabolic outcomes and treatment-related adverse effects.

This qualitative study evaluates experiences of heart and kidney care among women with diabetes. The primary objective is to identify barriers, supports, and care needs related to cardiovascular and kidney health, and to better understand how healthcare delivery can be optimized for this population. Participants will complete a one-time semi-structured interview with a trained member of the research team. Interviews may be conducted in person, by phone, or virtually and will explore experiences with diabetes care, management of heart and kidney health, and perspectives on improving care delivery. Interviews will be recorded and transcribed for analysis, and clinical context may be collected where relevant to support interpretation of findings.

Louise Moist

OK-TRANSPLANT 2 is a pragmatic, open-label vanguard study evaluating the feasibility of a weight loss intervention for patients with obesity and high-risk CKD or ESKD seeking kidney transplantation. Participants are randomized to receive either a virtual weight management program, which includes semaglutide and coaching, or standard of care. The study assesses recruitment feasibility, treatment adherence over 26 weeks, and the safety profile of GLP-1RA therapy in this specific population. The primary objective is to determine the viability of a larger multicenter trial aimed at reducing BMI-related barriers to transplant waitlisting.